MedTrace Logo

Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR

NCT01135316 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2

Last updated 2014-05-07

No results posted yet for this study

Summary

Phase 4, open-label, two-year, prospective, multi-center, follow-up study conducted at up 15 sites in USA. Approximately 1,000 patients with moderate-to-severe CKD will be enrolled and followed for up to 24 months.

Conditions

  • Nephrogenic Systemic Fibrosis

Interventions

DRUG

Ablavar

One dose of Ablavar will be administered for use during a contrast MRI examination

Sponsors & Collaborators

  • Lantheus Medical Imaging

    lead INDUSTRY

Principal Investigators

  • Simon P Robinson, PhD · Lantheus Medical Imaging

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01135316 on ClinicalTrials.gov